GLP 1 Drug Biosimilar Market Size, Share & Trends Analysis by Reference Biologic (Semaglutide Biosimilar, Liraglutide Biosimilar, Exenatide Biosimilar, Dulaglutide Biosimilar), by Formulation (Injectable Pen, Oral Tablet, Patch & Implant), by Distribution (Retail Pharmacy, Mail-Order & Specialty Pharmacy, Hospital & Clinic), and Segment Forecasts, 2026 to 2035 GLP-1 biosimilars are biological medicines developed to be highly similar in quality, safety, and efficacy to the originator GLP-1 receptor agonists, such as semaglutide, liraglutide, and dulaglutide
Primary analysis using trial product estimand found that bodyweight was significantly decreased in the active treatment groups
Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven P, Zieve F, Marks J, Davis S, Hayward R, et al: Glucose control and vascular complications in veterans with type 2 diabetes
It's really fascinating